Michelle Iandiorio, MD
Internal Medicine · Albuquerque, NMNPI 1063508711
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Gilead accounts for 83.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $289 and has fallen 92.9% since, to $21 in 2025.
Across 20 payments — averaging $48.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$809
- Merck$91
- Viiv Healthcare Company$50
- Bristol Myers Squibb$21
Across 58 payments — averaging $6033.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$245K
- AbbVie$75K
- Merck$17K
- Janssen Research & Development, LLC$14K
What the payments were for
- Food & beverage$971100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 15 | $809 |
| Merck | 1 | $91 |
| Viiv Healthcare Company | 3 | $50 |
| Bristol Myers Squibb | 1 | $21 |
How this compares
$971 in reported general payments places this provider in the 85th percentile of 578 internal medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 706 | $2,746,743 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 64 | $321,805 |
| TivicayDolutegravir Sodium | 111 | $267,364 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 44 | $156,302 |
| PrezcobixDarunavir/Cobicistat | 65 | $148,530 |
| DovatoDolutegravir Sodium/Lamivudine | 51 | $142,316 |
| JulucaDolutegravir/Rilpivirine | 35 | $121,912 |
| CabenuvaCabotegravir/Rilpivirine | 14 | $105,516 |
| RukobiaFostemsavir Tromethamine | 12 | $95,008 |
| DescovyEmtricitabine/Tenofov Alafenam | 37 | $87,652 |
| PifeltroDoravirine | 33 | $70,732 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 18 | $65,038 |
| TrulicityDulaglutide | 44 | $44,585 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 11 | $38,731 |
| EliquisApixaban | 56 | $37,136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $809 | $2,873,126754 claims |
| Viiv Healthcare CompanyTivicay, Dovato, Juluca, Cabenuva, Rukobia | $50 | $797,154241 claims |
| MerckPifeltro | $91 | $70,73233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 578 internal medicine providers in New Mexico.
Other internal medicine in Albuquerque
- Edward LewieckiAlbuquerque$491K
- James AdairAlbuquerque$108K
- Gulshan ParasherAlbuquerque$66K
- Mark WalkerAlbuquerque$24K
- Joao TeixeiraAlbuquerque$18K
- Karla AlmarazAlbuquerque$18K
- David SosaAlbuquerque$11K
- Revati ReddyAlbuquerque$7K
- Ross DavidsonAlbuquerque$7K
- Edmee RodriguezAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.